A groundbreaking study published in the journal Current Neuropharmacology has revealed a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists, widely used in blockbuster drugs like Ozempic, and the risk of depression and suicidal ideation. The research, led by an international team of 24 researchers, found genetic pathways that may induce depressive phenotypes in users of GLP1 agonists.
The study suggests that while GLP1 agonists benefit individuals with hyperdopaminergia (excess dopamine activity), they may have harmful effects on individuals with hypodopaminergia (low dopamine function). The authors identified genetic associations between GLP1 receptor agonists and genes such as DRD3, BDNF, and CREB1, which are implicated in mood regulation and reward pathways.
The findings of the study raise significant concerns about the safety of these medications for certain individuals. Experts warn that chronic use of GLP1 agonists could dysregulate dopamine signaling, potentially leading to depressive symptoms, mood disturbances, and suicidal ideation.
Regulatory agencies, such as the FDA and EMA, are already taking notice, with the European Medicines Agency initiating a review of GLP1 agonists following reports of suicidal thoughts and other psychiatric adverse events. The study advocates for personalized medicine approaches, including genetic testing for hypodopaminergia, to identify individuals at risk before prescribing GLP1 receptor agonists.
While GLP1 receptor agonists hold promise for treating addictive and behavioral disorders, experts emphasize the need for caution when prescribing these medications. A balance must be struck between hope and vigilance, as the study’s findings serve as a critical reminder of the potential risks associated with these medications.
Source: https://www.news-medical.net/news/20250417/GLP1-agonists-linked-to-depression-risk-in-new-genetic-study.aspx